3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
10
Phase NA
5
Phase 2/3
2
Phase 1
2
Phase 3
1
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
1
Genitourinary
1
Conditions
Lymphoma, Follicular
200
Lymphoma
199
Lymphoma, Non-Hodgkin
167
Leukemia, Lymphocytic, Chronic, B-Cell
166
Lymphoma, Large B-Cell, Diffuse
163
Precursor Cell Lymphoblastic Leukemia-Lymphoma
154
Leukemia
89
Hodgkin Disease
89
Lymphoma, Mantle-Cell
80
Lymphoma, B-Cell, Marginal Zone
66
Burkitt Lymphoma
65
Leukemia, Myeloid, Acute
55
Multiple Myeloma
52
Lymphoma, Large-Cell, Immunoblastic
48
Recurrence
44
Neoplasms
38
Myelodysplastic Syndromes
38
Lymphoma, T-Cell, Cutaneous
36
Mycosis Fungoides
30
Lymphoma, Large-Cell, Anaplastic
30
Waldenstrom Macroglobulinemia
28
Leukemia, Myeloid, Chronic-Phase
28
Myeloproliferative Disorders
27
Lymphoma, B-Cell
27
Leukemia, Myeloid, Accelerated Phase
27
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
26
Sezary Syndrome
25
Leukemia, Biphenotypic, Acute
25
Blast Crisis
24
Primary Myelofibrosis
22
Interventions
Standard of Care
1
Atorvastatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
COVID-19
×
Lymphoid
×
Clear all
NCT04904536
2025-04-10
STRONGER
The George Institute
Phase 3
Active not recruiting
190 enrolled